Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 Gag, Pol, Env, Nef, Tat, and Vif proteins represent the core structural, enzymatic, and regulatory machinery of the Human Immunodeficiency Virus type 1. Gag provides the structural framework for viral assembly, while Pol encodes the essential enzymes—protease, reverse transcriptase, and integrase—required for the viral life cycle (UniProt P04591, P03367). Env facilitates viral entry into host CD4+ T cells through its surface glycoproteins gp120 and gp41 (UniProt P04578). The regulatory proteins Tat and Nef, along with the accessory protein Vif, modulate the host cell environment to enhance viral transcription and evade the host immune response (UniProt P04608, P03406, P03401). Collectively, these proteins are the primary targets for antiretroviral therapy (ART) and are frequently utilized as antigens in the development of therapeutic and preventative HIV vaccines (NIH HIVinfo).
Inhibition of viral reverse transcription, integration of viral DNA, proteolytic processing of polyproteins, viral entry/fusion, and capsid assembly/disassembly (NIH HIVinfo).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 Gag, Pol, Env, Nef, Tat, and Vif proteins (HIV-1 Gag/Pol/Env/Nef/Tat/Vif).